• By ICR Secretariat
  • Posted Wednesday, November 20, 2019

Solid gene therapy trial halted again by FDA


The Food and Drug Administration ordered a clinical hold on a trial of Solid Biosciences' gene therapy for Duchenne muscular dystrophy after a patient experienced an immune response accompanied with blood, kidney, heart and lung complications.